All News #Library
Biotech
OrsoBio Hits Target In Midstage Study For Metabolic Conditions
10 Feb 2026 //
FIERCE BIOTECH
Orsobio Validates First-In-Class LXR Inverse Agonist TLC-2716
16 Jan 2026 //
BUSINESSWIRE
OrsoBio Announces Positive Data for Oral Tirzepatide TLC-6740
16 Dec 2025 //
BUSINESSWIRE
Orsobio To Showcase Mitochondrial Protonophore Portfolio
04 Nov 2025 //
BUSINESSWIRE
OrsoBio Raises $67M For Mitochondrial Protonophore Obesity Portfolio
06 Sep 2024 //
BUSINESSWIRE

Market Place
Sourcing Support